Brief: Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia
18/08/2026 13:31
BRIEF-Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia Aug 18 (Reuters) - BioMarin Pharmaceutical Inc. BMRN.O:
BIOMARIN TO ACQUIRE ALESTA THERAPEUTICS TO GAIN ALE1, A POTENTIAL FIRST ORAL THERAPY FOR HYPOPHOSPHATASIA, ADDING AN IMPORTANT CLINICAL PROGRAM TO BIOMARIN'S PIPELINE
BIOMARIN PHARMACEUTICAL - TO PAY $275 MILLION UPFRONT PLUS MILESTONE PAYMENTS FOR ALESTA
BIOMARIN PHARMACEUTICAL - ALESTA TO SPIN OUT NON-ALE1 ASSETS AND EMPLOYEES BEFORE CLOSE
BIOMARIN PHARMACEUTICAL - ALESTA SHAREHOLDERS ELIGIBLE FOR UP TO $215 MILLION IN MILESTONE PAYMENTS
BIOMARIN PHARMACEUTICAL - TO FUND ACQUISITION WITH CASH ON HAND
BIOMARIN PHARMACEUTICAL - DEAL EXPECTED TO BE MODESTLY DILUTIVE TO 2026 FINANCIAL RESULTS
Source text: ID:nPnb1BtMra
Further company coverage: BMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife